207 related articles for article (PubMed ID: 38617746)
21. Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues.
Agarwal P; Mohamed A
Curr Treat Options Oncol; 2022 Sep; 23(9):1233-1246. PubMed ID: 35939200
[TBL] [Abstract][Full Text] [Related]
22. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Saif MW
Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
[TBL] [Abstract][Full Text] [Related]
23. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
Cives M; Soares HP; Strosberg J
Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
[TBL] [Abstract][Full Text] [Related]
24. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
Strosberg JR
Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
[TBL] [Abstract][Full Text] [Related]
25. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
26. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
27. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review.
Berardi R; Rinaldi S; Torniai M; Morgese F; Partelli S; Caramanti M; Onofri A; Polenta V; Pagliaretta S; Falconi M; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():264-74. PubMed ID: 26643525
[TBL] [Abstract][Full Text] [Related]
29. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
[TBL] [Abstract][Full Text] [Related]
30. Multidisciplinary management of refractory insulinomas.
Brown E; Watkin D; Evans J; Yip V; Cuthbertson DJ
Clin Endocrinol (Oxf); 2018 May; 88(5):615-624. PubMed ID: 29205458
[TBL] [Abstract][Full Text] [Related]
31. Real-world study of everolimus in advanced progressive neuroendocrine tumors.
Panzuto F; Rinzivillo M; Fazio N; de Braud F; Luppi G; Zatelli MC; Lugli F; Tomassetti P; Riccardi F; Nuzzo C; Brizzi MP; Faggiano A; Zaniboni A; Nobili E; Pastorelli D; Cascinu S; Merlano M; Chiara S; Antonuzzo L; Funaioli C; Spada F; Pusceddu S; Fontana A; Ambrosio MR; Cassano A; Campana D; Cartenì G; Appetecchia M; Berruti A; Colao A; Falconi M; Delle Fave G
Oncologist; 2014 Sep; 19(9):966-74. PubMed ID: 25117065
[TBL] [Abstract][Full Text] [Related]
32. Management of pulmonary neuroendocrine tumors.
Ramirez RA; Chauhan A; Gimenez J; Thomas KEH; Kokodis I; Voros BA
Rev Endocr Metab Disord; 2017 Dec; 18(4):433-442. PubMed ID: 28868578
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives.
Modica R; Liccardi A; Minotta R; Cannavale G; Benevento E; Colao A
Expert Rev Endocrinol Metab; 2022 Sep; 17(5):389-403. PubMed ID: 35822906
[TBL] [Abstract][Full Text] [Related]
34. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.
Yoo C; Oh CR; Kim ST; Bae WK; Choi HJ; Oh DY; Lee MA; Ryoo BY
Cancer Res Treat; 2021 Apr; 53(2):291-300. PubMed ID: 33421978
[TBL] [Abstract][Full Text] [Related]
35. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
36. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Kulke MH; Ruszniewski P; Van Cutsem E; Lombard-Bohas C; Valle JW; De Herder WW; Pavel M; Degtyarev E; Brase JC; Bubuteishvili-Pacaud L; Voi M; Salazar R; Borbath I; Fazio N; Smith D; Capdevila J; Riechelmann RP; Yao JC
Ann Oncol; 2017 Jun; 28(6):1309-1315. PubMed ID: 28327907
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Uprety D; Halfdanarson TR; Molina JR; Leventakos K
Curr Treat Options Oncol; 2020 Aug; 21(11):86. PubMed ID: 32862320
[TBL] [Abstract][Full Text] [Related]
39. Systemic therapy for advanced pancreatic neuroendocrine tumors.
Kulke MH
Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
[TBL] [Abstract][Full Text] [Related]
40. Nonsurgical treatment of advanced malignant neuroendocrine pancreatic tumors and midgut carcinoids.
Skogseid B
World J Surg; 2001 Jun; 25(6):700-3. PubMed ID: 11376401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]